REYATAZ 150 mg, hard capsule 60 capsules
Active ingredients: Atazanavir, Atazanavir sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- REYATAZ 150 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 10 plaquette(s) thermoformée(s) aluminium de 6 gélule(s)
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69443966CIP73640438CIP133400936404380Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ATAZANAVIRgélule | 150 mg · une gélule | FT |
| ATAZANAVIR (SULFATE D')gélule | 170,8 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.